GILDNASDAQ— Gilead Sciences Inc Price & Analysis

Gilead Sciences Inc

HEALTHCARE — DRUG MANUFACTURERS - GENERAL

$156.04

-$1.15-0.73%

Market Cap: $194.91B; Large Cap
P/E Ratio: N/A; Fwd: 15.55
EPS (TTM): $-2.65
Div. Yield: 2.10%

Technical Summary

RSI (14)58.57Neutral

SMA (50)$148.50Bullish

SMA (200)$137.55Bullish

MACD2.4812Bullish

Bollinger$142.49 – $159.57Mid

Stochastic72.59Neutral

Theo Outlook

Gilead Sciences develops and commercializes antiviral medicines for HIV, hepatitis B, hepatitis C and influenza. For the trailing twelve months ended June 30, 2026 the company reported revenue of $30.46 billion, a profit margin of -10.6 percent, diluted earnings per share of -$2.65 and a market capitalization of $194.91 billion.

Bull case: quarterly earnings grew 54.8 percent year over year and quarterly revenue rose 10.2 percent year over year through June 30, 2026, while the forward price-to-earnings ratio stood at 15.55. Bear case: the trailing profit margin was -10.6 percent, diluted earnings per share were -$2.65 and the price-to-book ratio reached 16.

Key risks include negative profitability and a beta of 0.332. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Oct 23, 2026.

Company Overview

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Fundamental Snapshot

Revenue: $30.46B
EBITDA: $14.60B
Gross Profit: $24.25B
Operating Margin: 33.7%
Profit Margin: -10.6%
ROE: -20.7%
Book Value: $9.53
Beta: 0.33
52-Wk High: $160.51
52-Wk Low: $111.27
Volume: 6.01M
PEG Ratio: 2.27

Frequently Asked Questions

What does Gilead Sciences do?

Gilead Sciences develops and sells antiviral drugs for HIV, hepatitis B, hepatitis C and influenza. The company is headquartered in Foster City, California.

Where does Gilead Sciences's revenue come from?

Revenue totaled $30.46 billion for the trailing twelve months ended June 30, 2026. The company focuses on antiviral medicines including Harvoni and Sovaldi.

How does Gilead Sciences compete?

Gilead Sciences competes through its portfolio of approved antiviral therapies and ongoing research. Its trailing twelve months revenue reached $30.46 billion as of June 30, 2026.

What are the main risks for Gilead Sciences?

The company reported a profit margin of -10.6 percent and diluted earnings per share of -$2.65 for the trailing twelve months ended June 30, 2026. Its beta stood at 0.332.

How is Gilead Sciences valued?

The forward price-to-earnings ratio was 15.55, the price-to-book ratio was 16 and the enterprise value to revenue ratio was 6.97 as of the latest data. The trailing price-to-sales ratio was 6.4.